Trophoblast Cell Surface Antigen 2 Expression in Human Tumors: A Tissue Microarray Study on 18,563 Tumors
Pathobiology · 2022 · 89 (4) · 245-258
DOI: 10.1159/000522206 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathobiology, online erschienen am 27.04.2022. Verfasst von David Dum und 23 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Hauptthemen laut MEDLINE: Adenocarcinoma, Carcinoma, Transitional Cell, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 113-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Trophoblast cell surface antigen 2 (TROP2) is the target of sacituzumab govitecan, an antibody-drug conjugate approved for treatment of triple negative breast cancer and urothelial carcinoma.
Methods
A tissue microarray containing 18,563 samples from 150 different tumor types and subtypes as well as 608 samples of 76 different normal tissue types was analyzed by TROP2 immunohistochemistry.
Results
TROP2 positivity was found in 109 tumor categories, including squamous cell carcinomas of various origins, urothelial, breast, prostate, pancreatic, and ovarian cancers (>95% positive). High TROP2 expression was linked to advanced stage (p = 0.0069) and nodal metastasis (p < 0.0001) in colorectal cancer as well as to nodal metastasis in gastric adenocarcinoma (p = 0.0246) and papillary thyroid cancer (p = 0.0013). Low TROP2 expression was linked to advanced stage in urothelial carcinoma (p < 0.0001), high pT (p = 0.0024), and high grade (p < 0.0001) in breast cancer, as well as with high Fuhrmann grade (p < 0.0001) and pT stage (p = 0.0009) in papillary renal cell carcinomas.
Conclusion
TROP2 is expressed in many epithelial neoplasms. TROP2 deregulation can be associated with cancer progression in a tumor-type dependent manner. Since anti-TROP2 cancer drugs have demonstrated efficiency, they may be applicable to a broad range of tumor entities in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Department of Pathology, Academic Hospital Fuerth, Fuerth, Germany.
- Institute of Pathology, Clinical Center Osnabrueck, Osnabrueck, Germany.
Zitieren
APA
Dum, D., Taherpour, N., Menz, A., Höflmayer, D., Völkel, C., Hinsch, A., Gorbokon, N., Lennartz, M., Hube-Magg, C., Fraune, C., Bernreuther, C., Lebok, P., Clauditz, T. S., Jacobsen, F., Sauter, G., Uhlig, R., Wilczak, W., Steurer, S., Minner, S., …, & Luebke, A. M. (2022). Trophoblast Cell Surface Antigen 2 Expression in Human Tumors: A Tissue Microarray Study on 18,563 Tumors. Pathobiology, 89(4), 245-258. https://doi.org/10.1159/000522206
Vancouver
Dum D, Taherpour N, Menz A, Höflmayer D, Völkel C, Hinsch A, et al. Trophoblast Cell Surface Antigen 2 Expression in Human Tumors: A Tissue Microarray Study on 18,563 Tumors. Pathobiology. 2022;89(4):245-258. doi:10.1159/000522206
BibTeX
@article{Dum2022,
author = {Dum, David and Taherpour, Noushin and Menz, Anne and Höflmayer, Doris and Völkel, Cosima and Hinsch, Andrea and Gorbokon, Natalia and Lennartz, Maximilian and Hube-Magg, Claudia and Fraune, Christoph and Bernreuther, Christian and Lebok, Patrick and Clauditz, Till S and Jacobsen, Frank and Sauter, Guido and Uhlig, Ria and Wilczak, Waldemar and Steurer, Stefan and Minner, Sarah and Marx, Andreas H and Simon, Ronald and Burandt, Eike and Krech, Till and Luebke, Andreas M},
title = {Trophoblast Cell Surface Antigen 2 Expression in Human Tumors: A Tissue Microarray Study on 18,563 Tumors},
journal = {Pathobiology},
year = {2022},
volume = {89},
number = {4},
pages = {245--258},
doi = {10.1159/000522206}
}
EUVIMED